Our top pick for
Cellect Biotechnology Ltd is a biotechnology business based in the US. Cellect Biotechnology shares (APOP) are listed on the NASDAQ and all prices are listed in US Dollars. Cellect Biotechnology employs 14 staff and has a market cap (total outstanding shares value) of USD$14.3 million.
|52-week range||USD$0.4 - USD$4.34|
|50-day moving average||USD$3.1885|
|200-day moving average||USD$2.4572|
|Wall St. target price||USD$12|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.854|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Gross profit TTM||USD$0|
|Return on assets TTM||-37.99%|
|Return on equity TTM||-99.63%|
|Market capitalisation||USD$14.3 million|
TTM: trailing 12 months
There are currently 24,854 Cellect Biotechnology shares held short by investors – that's known as Cellect Biotechnology's "short interest". This figure is 54.6% down from 54,694 last month.
There are a few different ways that this level of interest in shorting Cellect Biotechnology shares can be evaluated.
Cellect Biotechnology's "short interest ratio" (SIR) is the quantity of Cellect Biotechnology shares currently shorted divided by the average quantity of Cellect Biotechnology shares traded daily (recently around 191184.61538462). Cellect Biotechnology's SIR currently stands at 0.13. In other words for every 100,000 Cellect Biotechnology shares traded daily on the market, roughly 130 shares are currently held short.
However Cellect Biotechnology's short interest can also be evaluated against the total number of Cellect Biotechnology shares, or, against the total number of tradable Cellect Biotechnology shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Cellect Biotechnology's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Cellect Biotechnology shares in existence, roughly 10 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Cellect Biotechnology shares, roughly 0 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Cellect Biotechnology.
Find out more about how you can short Cellect Biotechnology stock.
We're not expecting Cellect Biotechnology to pay a dividend over the next 12 months.
Cellect Biotechnology's shares were split on a 1:5 basis on 23 October 2019. So if you had owned 5 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Cellect Biotechnology shares – just the quantity. However, indirectly, the new 400% higher share price could have impacted the market appetite for Cellect Biotechnology shares which in turn could have impacted Cellect Biotechnology's share price.
Over the last 12 months, Cellect Biotechnology's shares have ranged in value from as little as $0.4 up to $4.34. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cellect Biotechnology's is 1.9368. This would suggest that Cellect Biotechnology's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Cellect Biotechnology Ltd., a biotechnology company, engages in developing ApoGraft, a technology platform that functionally selects stem cells to enhance the safety of regenerative medicine and stem cell therapies in Israel. It is developing the ApoTainer selection kit, a shelf stem cell selection kit for allogeneic hematopoietic stem cell transplantation procedures for patients suffering from hematological malignancies. The company has collaborations with the denovoMATRIX group of the Technische Universität Dresden to conduct examinations into the tentative synergy between ApoGraft and denovoMAtrix technology for the purpose of evaluating collaborative development of products for regenerative medicine; and Cell2in Inc. to conduct scientific evaluations combining ApoGraft with Cell2in's identification technology FreSHtracer, which monitors stem cell quality by utilizing a fluorescent dye to characterize their oxidative stress state. It also has a collaboration with the Washington University School of Medicine to determine the safety and tolerability of ApoGraft for bone marrow transplantations in the United States. The company was formerly known as Cellect Biomed Ltd. and changed its name to Cellect Biotechnology Ltd. in July 2016. Cellect Biotechnology Ltd. was founded in 2011 and is headquartered in Kfar Saba, Israel.
If you’re looking for a broker comparable to Vanguard, check out these five contenders.
Thinking of switching from TD Ameritrade? Here are 5 apps like TD Ameritrade that offer valuable benefits.
Our picks of the best overwater stays in the Land of Smiles from budget-friendly to luxurious.
This guide will show you step-by-step instructions on how to buy the Reserve Rights (RSR) token as well as a list of exchanges you can trade it on.
This guide will show you step-by-step instructions on how to buy the Curve (CRV) token as well as a list of exchanges you can trade it on.
Acorns alternatives offer lower fees and more investment options. Learn more.
Hanna Andersson’s Organic Cotton Long John is comfortable and available in family sizes. Here’s what I thought of the fit, and details on sustainability.
Find in-stock face masks for wildires, smoke and dust, see our top picks and read tips for using respirator smoke masks.
The Chairman of Dubai’s IBC Group has pledged a whopping $4.8 billion into Bitcoin, as Microstrategy purchases another $1 billion of BTC.
This guide will show you step-by-step instructions on how to buy the Maker (MKR) token as well as a list of exchanges you can trade it on.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.